Alnylam Pharmaceuticals
ALNY
315 hedge funds and large institutions have $12.3B invested in Alnylam Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 72 funds opening new positions, 98 increasing their positions, 98 reducing their positions, and 29 closing their positions.
148% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 29
41% more capital invested
Capital invested by funds: $8.69B → $12.3B (+$3.56B)
13% more funds holding
Funds holding: 280 → 315 (+35)
11% more call options, than puts
Call options by funds: $155M | Put options by funds: $139M
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
0% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 98
2.23% less ownership
Funds ownership: 97.18% → 94.95% (-2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$92.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$46.6M |
| 3 |
AG
Artal Group
Luxembourg
|
+$29.9M |
| 4 |
SPC
Slate Path Capital
New York
|
+$19.9M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
-$95.9M |
| 2 |
FAM
Fred Alger Management
New York
|
-$56.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$54.5M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$37.3M |
| 5 |
Goldman Sachs
New York
|
-$30.9M |
ALNY Hedge Fund Activity: Q4 2019 in Review
315 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2019, worth a combined $12.3B — up 41% from $8.69B a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new ALNY positions and 29 closed out — a net gain of 43 holders — while 98 added to existing stakes and 98 trimmed.
The largest buyer was BlackRock, adding an estimated $92.5M. The largest seller was Maverick Capital, cutting an estimated $95.9M.
- 315 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2019, up from 280 in Q3 2019.
- Funds reported $12.3B of Alnylam Pharmaceuticals stock for Q4 2019, up 41% quarter-over-quarter.
- 72 funds opened new Alnylam Pharmaceuticals positions in Q4 2019 and 29 closed out, a net change of +43 holders.
- The largest Alnylam Pharmaceuticals buyer in Q4 2019 was BlackRock, an estimated $92.5M added.
- The largest Alnylam Pharmaceuticals seller in Q4 2019 was Maverick Capital, an estimated $95.9M sold.
Based on aggregated 13F filings for Q4 2019.